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AIMS: Glucocorticoids (GCs) exert some of their anti-
inflammatory actions by preventing the activation of
the transcription factor nuclear factor (NF)-kB. The
GC-dependent inhibition of NF-kB may occur at
different levels, but the mechanisms involved are
still incompletely understood. In this work, we
investigated whether the synthetic GC, dexametha-
sone (Dex), modulates the activity of NF-kB in the
lymphoblastic CCRF-CEM cell line. We also evaluated
the ability of Dex to prevent the activation of NF-kBi n
response to the potent proinflammatory cytokine,
interleukin (IL)-1b.
Results: Exposure of the cells to Dex (1 mM) induced
the rapid degradation of IkB-a, leading to the tran-
sient translocation of the NF-kB family members p65
and p50 from the cytoplasm to the nucleus, as
evaluated by western blot. Electrophoretic mobility
shift assays revealed that, in the nucleus, these NF-kB
proteins formed protein 
/DNA complexes, indicating
a transient activation of NF-kB. Additionally, Dex also
induced de novo synthesis of IkB-a, following its
degradation. Finally, when the cells were exposed to
Dex (1 mM) prior to stimulation with IL-1b (20 ng/ml),
Dex was efficient in preventing IL-1b-induced NF-kB
activation. The GC antagonist, RU 486 (10 mM), did not
prevent any of the effects of Dex reported here.
Conclusion: Our results indicate that, in CCRF-CEM
cells, Dex prevents NF-kB activation, induced by IL-
1b, by a mechanism that involves the upregulation of
IkB-a synthesis, and that depends on the early and
transient activation of NF-kB.
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Introduction
The transcription factor nuclear factor (NF)-kBi s
composed of several structurally related (Rel) pro-
teins, which include p50 (and its precursor p105),
p52 (and its precursor p100), p65 (RelA), c-Rel and
RelB.
1 3 The Rel proteins can form either homo-
dimers or heterodimers with each other, except RelB,
which can only form heterodimers.
4 6
In resting cells, the NF-kB dimers are sequestered
in the cytoplasm in a latent inactive state, as the
result of binding to inhibitor proteins, namely
IkB-a, which is the major NF-kB inhibitor.
1,3
Upon stimulation by a variety of extracellular
signals, such as the proinflammatory cytokines,
ultraviolet light, ionizing radiation, bacterial
lipopolysaccharide and phorbol esters,
7 9 IkB-a
undergoes phosphorylation-dependent degradation,
thus releasing the active NF-kB dimers.
1,8 The
freed NF-kB dimers migrate into the nucleus,
and bind to specific kB DNA binding sites in the
promoter regions of susceptible genes,
thereby regulating the expression of a large number
of genes coding for proteins mainly involved
in immune and inflammatory responses.
1,9,10 Addi-
tionally, NF-kB has also been implicated in
the transcriptional regulation of the RelB
11 and IkB-
a
1,2,12 genes.
After stimulation, the activity of NF-kB is usually
transient,
1,3 as a consequence of the rapid re-synth-
esis of IkB-a following its degradation. Newly
synthesized IkB-a replenishes its cytoplasmic levels
and simultaneously enters the nucleus, where it binds
to the NF-kB dimers, thereby blocking their DNA
binding ability and restoring the cytoplasmic pool of
latent NF-kB.
1,2
Glucocorticoids (GCs) are potent immunosupres-
sive agents that, on one hand, may induce the
synthesis of anti-inflammatory mediators like annexin
1
13 and, on the other hand, may inhibit the expres-
sion of several cytokines and adhesion
molecules.
14 16 The anti-inflammatory effects of
GCs mediated by inhibition of gene expression
have been attributed to the capability of these
hormones to interfere with the activity of transcrip-
tion factors, namely NF-kB.
14,17,18 At least two distinct
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37mechanisms may be involved in the inhibition of NF-
kB by GCs: (i) a cross-coupling mechanism, in which
the activated GC receptor directly interacts with and
inhibits the activated NF-kB dimers;
19 21 and (ii) a
mechanism involving the transcriptional activation of
the IkB-a gene, that leads to the rapid replenishment
of its intracellular levels with the consequent block-
ade of NF-kB activity.
17,18,22,23 The physiological
relevance of these mechanisms has not been clearly
established, and it still remains unclear whether both
mechanisms participate in the inhibition of NF-kBb y
GCs.
In this work, we used the lymphoblastic
human CCRF-CEM cell line to study the mechanisms
involved in the inhibition of NF-kB by the syn-
thetic GC dexamethasone (Dex). We investigated
the ability of Dex alone to modulate NF-kB
activity, by evaluating the cytoplasmic levels of I
kB-a as well as the nuclear levels of NF-kB proteins
and their DNA-binding ability, in cells treated
with Dex. Moreover, we studied the involvement
of the GC receptors on these processes, using
the GC receptor antagonist RU486. Finally, we
investigated whether interleukin (IL)-1b, a proinflam-
matory cytokine with a potent NF-kB-inducing
activity in several cell types,
21,24,25 was able to
activate NF-kB in CCRF-CEM cells, and whether and
how Dex was able to prevent the effect of IL-1b.
Materials and methods
Chemicals
The human CCRF-CEM acute T-lymphoblastic
leukaemia cell line was purchased from
American Type Culture Collection (ATCC, Rockville,
MD, USA). Foetal calf serum (FCS) was obtained
from Biochrom (Berlin, Germany). Recombinant hu-
man interleukin-1b (IL-1b) was from R&D
Systems (Abingdon, UK). The protease inhibitor
cocktail was obtained from Roche (Manheim,
Germany). Oligonucleotide probes were from
Santa Cruz (Santa Cruz, CA, USA), whereas
[g-
32P]adenosine triphosphate, T4 polynucleotide
kinase, and poly(dI-dC) were obtained from
Amersham Biosciences (Piscataway, NJ, USA). The
rabbit polyclonal antibody against IkB-a was
purchased from Cell Signalling Tech. (Beverly,
MA, USA), whereas the rabbit polyclonal anti-
bodies against p65, p50, p52 and RelB, and the goat
polyclonal antibody against c-Rel were obtained from
Santa Cruz (Santa Cruz, CA, USA). The anti-actin
monoclonal antibody was purchased from Roche
(Manheim, Germany). The horseradish peroxidase-
conjugated anti-rabbit, anti-goat and anti-mouse
antibodies were obtained from Amersham Bios-
ciences (Piscataway, NJ, USA), Zymed (S. Francisco,
CA, USA) and Pierce (Rockford, IL, USA), respec-
tively. The Enhanced Chemiluminescence
(ECL) western blotting detection reagents were
purchased from Amersham Biosciences (Piscataway,
NJ, USA). All other reagents were from Sigma
Chemical Co. (St. Louis, MO, USA).
Culture conditions
The human CCRF-CEM acute T-lymphoblastic leu-
kaemia cell line was maintained in RPMI medium
supplemented with 10% (v/v) FCS, 100 mg/ml of
streptomycin and 100 U/ml of penicillin, at 378C, in
an atmosphere of 5% CO2/95% air. Prior to any
treatments, CCRF-CEM cells were plated at 5 /10
6
cells/well, in six-well culture dishes, in FCS-free RPMI
supplemented with antibiotics, for 6 h, and main-
tained in these conditions thereafter. In each experi-
ment, controls were always included, and consisted
of incubating the cells in the corresponding volume
of culture medium plus the appropriate vehicle.
Cell viability
Viability of CCRF-CEM cells under the various experi-
mental conditions was always assessed by the 3-(4,5-
dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bro-
mide (MTT) reduction method. Assessment of MTT
reduction by metabolically active cells was made by a
colourimetric assay, as previously described.
26
Preparation of cytoplasmic and nuclear extracts
After washing with ice-cold phosphate buffered
saline, the cells were lysed in buffer 1 (10 mM of
NaCl, 3 mM of MgCl2, 0.5% (v/v) Nonidet P-40, 1 mM
of dithiothreitol, 0.1 mM of phenylmethylsulfonyl-
fluoride, 10 mM of Tris /HCl, pH 7.5, and the
protease inhibitor cocktail) and incubated on ice for
15 min. After brief vortexing, the lysates were
centrifuged at 2300 /g for 10 min at 48C. The
supernatants (cytoplasmic extracts) were collected
and stored at   /708C until further use. The pellets
obtained were resuspended in buffer 2 (300 mM of
NaCl, 3 mM of MgCl2, 20% (v/v) glycerol, 1 mM of
dithiothreitol, 0.1 mM of phenylmethylsulfonylfluor-
ide, 0.2 mM of ethylenediamine tetraacetic acid, 20
mM of HEPES buffer, pH 7.5, and the protease
inhibitor cocktail), incubated on ice for 45 min and
centrifuged at 12,000 /g for 20 min at 48C. The
supernatants (nuclear extracts) were collected and
stored at   /708C until further use. The protein
concentration of the extracts was determined using
the bicinchoninic acid/copper (II) sulfate protein
assay kit.
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Samples of cytoplasmic and nuclear extracts (25 mg)
were diluted (1:1) in sodium dodecylsulfate denatur-
ating buffer (200 mM of Tris, 200 mM of bicine, 8 M of
urea, 4% sodium dodecylsulfate, 10% b-mercap-
toethanol and 0.2% bromophenol blue), boiled,
subjected to 12% sodium dodecylsulfate-polyacryla-
mide gel electrophoresis, and electrotransferred to a
polyvinylidene difluoride membrane. The membrane
was then blocked with 5% non-fat dry milk in Tris-
buffered saline with 0.1% Tween 20. IkB-a and NF-
kB proteins (p65, p50, p52, RelB and c-Rel) were
detected by incubation with their respective primary
antibodies, followed by incubation with a horse-
radish peroxidase-conjugated anti-rabbit or anti-goat
antibody. The immunocomplexes were visualized by
the ECL chemiluminescent method. The membranes
were subsequently stripped and reprobed with an
anti-actin antibody, to ensure an equal protein
loading.
Electrophoretic mobility shift assay
The double-stranded oligonucleotide probe specific
for NF-kB( 5 ?-AGT TGA GGG GAC TTT CCC AGG C-
3?) was end-labelled with [g-
32P]adenosine tripho-
sphate, by the T4 polynucleotide kinase, and purified
through Sephadex G-50 spin columns. Nuclear ex-
tracts (12.5 mg protein) were incubated for 40 min at
48C, with 100,000 cpm of [g-
32P]-labelled oligonu-
cleotide, in a buffer containing 100 mg/ml of poly(dI-
dC).poly(dI-dC), 20 mM of HEPES (pH 7.9), 1 mM of
MgCl2, 4% (w/v) Ficoll 400, 0.5 mM of dithiothreitol,
50 mM of KCl, and 1 mg/ml of bovine serum albumin.
The DNA /protein complexes were resolved by
electrophoresis on 7% non-denaturating polyacrila-
mide gels, in a buffer system containing 0.044 M of
Tris /Base (pH 8.0), 4.45 mM of boric acid and 1 mM
of ethylenediamine tetraacetic acid, at a constant
voltage of 150 V, for 3 h at room temperature. The
gels were dried and subjected to autoradiography. In
competition experiments, a 100-fold excess of un-
labelled oligonucleotide was added to the nuclear
extracts immediately before the addition of the
radiolabelled probe. For supershift analysis, anti-
p65, anti-p50 or anti-RelB antibodies (2 mg/reaction)
were incubated with the nuclear extracts from Dex-
treated cells, for 2 h before the addition of the
radiolabelled probe.
Statistical analysis
Results are presented as average9 /SD of at least three
different experiments, as indicated. Comparison of
data from more than two treatment groups was made
by the one-way analysis of variance with Dunnett’s
post test.
Results
Dex induces the degradation followed by de
novo synthesis of IkB-a
To evaluate the ability of Dex to modulate the levels
of IkB-a, western blot analysis was performed using
cytoplasmic extracts obtained from CCRF-CEM cells
treated with Dex in concentrations ranging from 50
nM to 1 mM, for 5 min /1 h. The results obtained
showed that the amount of IkB-a present in the
cytoplasmic extracts obtained from cells treated with
1 mM of Dex, for 5 min, was significantly lower than
that found in untreated cells. The other concentra-
tions of Dex did not affect the IkB-a levels at any of
the incubation times used (data not shown). There-
fore, 1 mM of Dex was the concentration used in all
the subsequent experiments performed in this work.
As shown in Fig. 1, treatment of the cells with Dex
for 5 min decreased, by 61.8%, the amount of IkB-a
found in the cytoplasm, whereas in cells treated for
15 min the cytoplasmic level of the protein increased,
approaching the amount found in control cells. After
a 30 min treatment, IkB-a reached a level significantly
higher than that of the control. The protein synthesis
inhibitor, cycloheximide (CHX), was used to investi-
gate whether the time-dependent accumulation of
IkB-a was due to de novo protein synthesis. CHX (20
mg/ml) did not reduce the viability of the CCRF-CEM
cells, as assessed by the MTT assay (data not shown).
Moreover, control experiments showed that CHX
alone did not affect the cytoplasmic level of IkB-a
under resting conditions (data not shown). Pretreat-
ment of the cells with CHX, for 1 h, completely
abrogated the appearance of IkB-a in cytoplasmic
extracts from cells treated with Dex, for 1 h, thus
showing that de novo protein synthesis is required for
the Dex-induced IkB-a accumulation in the cyto-
plasm that follows its initial degradation (Fig. 1).
The GC antagonist, RU486, was used to determine
whether the effects of Dex on the cytoplasmic level of
IkB-a could be attributed to activation of intracellular
GC receptors. Control experiments showed that
RU486, at concentrations up to 10 mM, did not reduce
the viability of CCRF-CEM cells, as assessed by the
MTT assay (data not shown). The results obtained
show that at concentrations ranging from 1 to 10 mM,
RU486 did not affect the cytoplasmic level of IkB-a
under resting conditions. Furthermore, RU486 did not
revert, at any of the concentrations used, the Dex-
induced degradation and re-synthesis of IkB-a in
CCRF-CEM cells (data not shown).
Dexamethasone upregulates IkB-a synthesis
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p65 and p50 from the cytoplasm to the nucleus
and increases the synthesis of RelB
To study the ability of Dex to modulate NF-kB activity
in CCRF-CEM cells, we evaluated the cytoplasmic and
nuclear levels of the individual members of the NF-
kB family. Matched cytoplasmic and nuclear extracts
were subjected to western blot analysis, with anti-
bodies against p65, p50, p52, RelB and c-Rel. As
shown in Figs. 2 and 3, treatment of the cells with
Dex (1 mM), for 15 /30 min, resulted in significant
reductions of the cytoplasmic levels (Fig. 2A and Fig.
3A) accompanied by corresponding increases in the
nuclear levels (Fig. 2B and Fig. 3B) of both p65 and
p50. Those changes were transient, since in cells
treated with Dex for 1 h the levels of both proteins in
nuclear and cytoplasmic extracts were similar to
those found under resting conditions. Therefore,
these results show that Dex alone is sufficient to
induce p65 and p50 translocation to the nucleus,
although both proteins rapidly returned to their
original cytoplasmic location.
On the other hand, the cytoplasmic and nuclear
levels of RelB increased continuously over the time
periods tested (Fig. 4). Nevertheless, accumulation of
RelB in the nucleus occurred more rapidly than in the
cytoplasm, where the increase was only observed in
cells treated with Dex for 30 min or longer. Since the
level of RelB increased in both subcellular compart-
ments, we used CHX to find whether de novo protein
synthesis accounted for those increases. The results
presented in Fig. 4A show that the level of RelB in
cytoplasmic extracts prepared from cells pretreated
with CHX for 1 h before addition of Dex, for 1 h, was
significantly lower than that found in extracts from
control cells. The nuclear level of RelB in cells
incubated with Dex was not affected by pretreatment
of the cells with CHX (data not shown). Taken
together, these results show that the accumulation
of RelB in the cytoplasm is dependent on de novo
protein synthesis.
Finally, treatment of CCRF-CEM cells with Dex did
not significantly modify the protein level and the
subcellular localization of p52 and c-Rel, which were
found to be constitutively expressed in the cytoplasm
and nucleus, or exclusively in the nucleus, respec-
tively (data not shown).
Dex induces a time-dependent NF-kB activation
To study NF-kB activation, we detected the presence
of active NF-kB proteins in nuclear extracts from
CCRF-CEM cells, by electrophoretic mobility shift
assay analysis, with an oligonucleotide probe con-
taining the specific consensus binding sequence for
this transcription factor. In nuclear extracts from cells
treated with Dex (1 mM) for 30 min, the intensity of
the band corresponding to the binding of nuclear
FIG. 1. Dex induces the degradation followed by the re-synthesis of the cytoplasmic protein IkB-a. CCRF-CEM cells were
treated with Dex (1 mM), for the indicated periods, in the absence or in the presence of CHX (20 mg/ml) for 1 h. The cytoplasmic
extracts were prepared as described in Materials and methods. The cytoplasmic IkB-a content was determined by western blot
analysis, using a rabbit polyclonal anti-IkB-a antibody (A), and the bands were quantiﬁed with an image analyser (B). The
results presented in the upper panel (A) are representative of three independent experiments. The data shown in the lower
panel (B) are the average 9 /SD of three independent experiments. ** pB/0.01, as determined by one-way analysis of variance
with Dunnett’s post test.
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32P]-labelled NF-kB probe was
significantly higher than that obtained with nuclear
extracts from control cells (Fig. 5, lanes 1 /3). The
effect of Dex on NF-kB binding to DNA was time
dependent; that is, the maximal intensity was ob-
served in nuclear extracts from cells treated with Dex
FIG. 2. Dex induces the translocation of the NF-kB protein p65 from the cytoplasm to the nucleus. CCRF-CEM cells were treated
with Dex (1 mM) for the indicated periods. The cytoplasmic and nuclear extracts were prepared as described in Materials and
methods. The p65 cytoplasmic (A) and nuclear (B) content were determined by western blot analysis, using a rabbit polyclonal
anti-p65 antibody, and the bands were quantiﬁed with an image analyser. The results presented in the upper panels are
representative of four independent experiments. The data shown in the lower panels are the average 9 /SD of four
independent experiments. ** pB/0.01, as determined by one-way analysis of variance with Dunnett’s post test.
FIG. 3. Dex induces the translocation of the NF-kB protein p50 from the cytoplasm to the nucleus. CCRF-CEM cells were treated
with Dex (1 mM) for the indicated periods. The cytoplasmic and nuclear extracts were prepared as described in Materials and
methods. The p50 cytoplasmic (A) and nuclear (B) content were determined by western blot analysis, using a rabbit polyclonal
anti-p50 antibody, and the bands were quantiﬁed with an image analyser. The results presented in the upper panels are
representative of four independent experiments. The data shown in the lower panels are the average 9 /SD of four
independent experiments. * pB/0.05 and ** pB/0.01, as determined by one-way analysis of variance with Dunnett’s post test.
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with Dex (lane 4) the intensity of the bands
decreased, approaching the DNA binding activity
found in control cells.
To evaluate the specificity of the complexes
formed, competition assays were performed by
incubation of nuclear extracts from Dex-treated (30
min) cells with the [
32P]-labelled NF-kB oligonucleo-
tide probe and with a 100-fold excess of unlabelled
oligonucleotide probes, specific for either NF-kB
(lane 9) or an unrelated transcription factor, octa-
mer-1 (lane 10). Only the unlabelled NF-kB probe
was effective in preventing the formation of specific
complexes between the proteins present in the
nuclear extracts and the labelled NF-kB probe. This
indicates that the bands detected in the autoradio-
grams represent the formation of specific complexes
between NF-kB proteins and the NF-kB-specific
oligonucleotide probe.
Supershift analysis performed by incubation of
nuclear extracts prepared from Dex-treated cells, for
30 min, with an antibody against p65, prior to the
addition of the labelled NF-kB probe, showed the
formation of slower migrating complexes that ap-
peared in the autoradiography close to the origin of
the gel (lane 7). This indicates that the supershifted
band contains the protein p65. In identical assays
using antibodies against p50 and RelB, no super-
shifted bands were detected, but the intensity of the
NF-kB /oligonucleotide probe complexes was greatly
reduced (lanes 6 and 8, respectively). This indicates
that binding of each antibody to NF-kB dimers,
containing each of those proteins, prevented their
binding to the NF-kB probe. These results indicate
that the NF-kB dimers that bind to the specific NF-kB
consensus sequence, in response to Dex, contain
p65, p50 and RelB, probably arranged in various
types of dimers that migrate differently, producing
the two bands seen on the autoradiograms.
RU486 (1 /10 mM) did not affect NF-kB activation in
the absence of Dex, and did not prevent the Dex-
induced NF-kB activation (data not shown), indicat-
ing that this response of the CCRF-CEM cells to Dex is
not mediated by the intracellular GC receptors.
Dex prevents IL-1b-induced NF-kB activation
To determine whether Dex affects the activation of
NF-kB elicited by other stimuli, we investigated the
effect of this synthetic GC on the IL-1b-induced NF-
kB activation. Treatment of the cells with IL-1b alone
for 30 min resulted in the disappearance of IkB-a
from the corresponding cytoplasmic extracts. In
contrast, when the cells were pretreated with Dex
(1 mM) before the addition of IL-1b (20 ng/ml), for 30
min, the cytoplasmic level of IkB-a remained iden-
tical to that found in the control (Fig. 6A). Moreover,
the results presented in Fig. 6B show that IL-1b
significantly increased the intensity of the bands
corresponding to the NF-kB /DNA complexes rela-
FIG. 4. Dex induces the translocation of the NF-kB protein RelB from the cytoplasm to the nucleus. CCRF-CEM cells were
treated with Dex (1 mM), for the indicated periods, in the absence or in the presence of CHX (20 mg/ml) for 1 h. The cytoplasmic
and nuclear extracts were prepared, as described in Materials and methods. The RelB cytoplasmic (A) and nuclear (B) content
were determined by western blot analysis, using a rabbit polyclonal anti-RelB antibody, and the bands were quantiﬁed with an
image analyser. The results presented in the upper panels are representative of four independent experiments. The data
shown in the lower panels are the average9 /SD of four independent experiments. * pB/0.05 and ** pB/0.01, as determined by
one-way analysis of variance with Dunnett’s post test.
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pretreatment of the cells with Dex effectively pre-
vented IL-1b-induced NF-kB activation (lane 3).
Discussion
Inhibition of transcription factors, like NF-kB, is
considered a major mechanism by which GCs block
inflammation and suppress the activation of the
immune system.
14,15,27 Although many studies have
focused on the ability of GCs to prevent NF-kB
activation in response to a wide variety of sti-
muli,
19,23,24 the mechanisms involved in this inhibi-
tion are still incompletely understood. In the present
work, we investigated whether and how Dex mod-
ulates NF-kB activity in CCRF-CEM cells. The results
obtained show that Dex alone induced a transient
NF-kB activation, as revealed by its ability to induce
IkB-a degradation (Fig. 1), the translocation to the
nucleus of p65 and p50 (Fig. 2 and Fig. 3) and NF-
kB /DNA binding (Fig. 5). Furthermore, we found
FIG. 5. Activation of NF-kB by Dex. CCRF-CEM cells were treated (lanes 2 /4) or not (control, lane 1) with Dex (1 mM), for the
indicated periods. Nuclear extracts were prepared and subjected to electrophoretic mobility shift assay analysis as described
in Materials and methods. Supershift experiments were performed using antibodies against p50 (lane 6), p65 (lane 7) or RelB
(lane 8) in nuclear extracts from cells treated with Dex, for 30 min. Competition experiments with a 100-fold excess of
unlabelled competitor probe relatively to the labelled NF-kB probe were also performed using nuclear extracts from cells
treated with Dex, for 30 min (lanes 9 and 10). The results are representative of three independent experiments.
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proinflammatory cytokine IL-1b (Fig. 6).
The effect of Dex on the cytoplasmic levels of IkB-
a was biphasic. After the rapid decrease of the
protein levels within the first 5 min of stimulation
with Dex, the levels of the protein increased in a
time-dependent manner, becoming even higher then
those found in control cells (Fig. 1). These results,
together with the ability of CHX to prevent the
increase of the IkB-a levels elicited by Dex (Fig. 1),
suggest that this synthetic GC induced de novo
synthesis of IkB-a protein.
The initial translocation of p65 and p50 to the
nucleus was quickly followed by their return to the
cytoplasm, where these proteins reached levels
identical to those found in control cells, after 1 h
treatment with Dex (Figs. 2 and 3). The rapid
decrease in the IkB-a levels in the cytoplasm, most
probably due to a degradation of the protein,
1,8 was
correlated with a fast translocation of p65 and p50 to
the nucleus. Furthermore as observed for IkB-a, the
cytoplasmic levels of p65 (Fig. 2) and p50 (Fig. 3)
showed a secondary increase in cells incubated with
Dex for 1 h. Gel shift analysis showed that the
intensity of the NF-kB /DNA complexes, which
contained p65, p50 and RelB, increased over time,
reaching the maximum intensity in cells treated with
Dex for 30 min. After the initial increase, the intensity
of the NF-kB /DNA complexes decreased in cells
treated with Dex for 1 h (Fig. 5), which correlates
with the observed increase in the amount of p65 and
p50 present in the cytoplasm. These results suggest
that these NF-kB subunits migrate back to the
cytoplasm after exerting their effect in the nucleus.
Induction of IkB-a expression is one of the
mechanisms by which GCs can inhibit NF-kB activa-
tion in several cells.
17,18,22,23 Increased synthesis of
the IkB-a protein, following its loss, functions as a
negative feedback control mechanism since, once re-
synthesized, IkB-a enters the nucleus, binds to the
NF-kB proteins and thus inhibits NF-kB /DNA bind-
ing.
1,2 Furthermore, once bound to the NF-kB
proteins, IkB-a may transport them back to the
cytoplasm, hence re-establishing their cytoplasmic
pool.
7,8,10 In agreement with other reports, our
results also suggest that initial activation of NF-kB
by Dex was terminated due to the quick replenish-
ment of the cytoplasmic IkB-a levels, which resulted
from induction of the synthesis of this inhibitory
protein in response to Dex.
NF-kB, particularly p65, has been shown to
upregulate the transcription of the IkB-a gene, which
contains multiple NF-kB binding sites that are func-
tional in upregulating IkB-a gene expression in
response to stimuli that activate NF-kB.
1,2,12 There-
fore, our results suggest that the observed increase in
FIG. 6. Dex prevents IL-1b-induced NF-kB activation. CCRF-CEM cells were treated with IL-1b (20 ng/ml) for 30 min in the
absence (lane 2) or in the presence of Dex (1 mM for 1 h; lane 3), or left untreated (control, lane 1). Cytoplasmic and nuclear
extracts were prepared as described in Materials and methods. (A) The cytoplasmic IkB-a content was determined by western
blot analysis, using a rabbit polyclonal anti-IkB-a antibody, and the bands were quantiﬁed with an image analyser. The results
presented in the left panel are representative of four independent experiments. The data shown in the right panel are an
average 9 /SD of four independent experiments. ** pB/0.01, as determined by one-way analysis of variance with Dunnett’s
post test. (B) Nuclear extracts from cells subjected to the same experimental conditions were analysed by electrophoretic
mobility shift assay. The results are representative of three independent experiments.
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result of the Dex-induced NF-kB activation.
In human T cells (Jurkat cells)
18 and in brain
cells,
22 the induction of IkB-a synthesis by GCs has
been reported to be mediated by the GC receptor.
Therefore, we used the potent GC receptor antago-
nist, RU486, to investigate whether the effects of Dex
on IkB-a synthesis and NF-kB activation were
mediated through intracellular GC receptors. The
results obtained showed that pretreatment of the
cells with RU486 (1 /10 mM) did not prevent the early
Dex-induced IkB-a degradation and NF-kB /DNA
binding (data not shown), thus suggesting that the
effects of Dex on NF-kB reported in this work are
independent of the activation of the intracellular GC
receptors.
Additionally, treatment of CCRF-CEM cells with
Dex induced a parallel increase of both the cytoplas-
mic and the nuclear levels of RelB, which was
prevented by CHX, indicating that, in these cells,
this protein is also newly synthesized in response to
Dex (Fig. 4A). These results are in agreement with
others which showed that Dex also induced the
expression and nuclear localization of RelB in T
cells.
11 Moreover, while most NF-kB proteins are
sequestered in the cytoplasm by IkB-a, RelB is
not.
6,11,28 Instead, the translocation of RelB from the
cytoplasm to the nucleus appears to be a function of
its synthesis
6,11 (i.e. occurring in response to in-
creased synthesis). This may explain the parallel
augmentation of both cytoplasmic and nuclear levels
of RelB in cells exposed to Dex (Fig. 4).
Like the IkB-a gene, the RelB gene is also
susceptible to transcriptional induction by NF-kB.
11
Therefore, it is possible that de novo RelB synthesis
as well as de novo IkB-a synthesis are both mediated
by the early and transient activation of NF-kB dimers
during the initial response to Dex.
Taken together, the results presented in Figs. 1 /5
show that, in an early phase, Dex activates NF-kBi n
CCRF-CEM cells, quickly followed by repression of
the activity of this transcription factor. Nevertheless,
these results might argue against a NF-kB-mediated
anti-inflammatory action of Dex in these cells, in
contrast to what has been described.
14 16,18 To
elucidate this question, we investigated the effect of
Dex on the activation of NF-kB by IL-1b, a known
proinflammatory cytokine. IL-1b is a potent NF-kB
activator, which induces the rapid degradation of
IkB-a, thereby promoting the translocation of the NF-
kB dimers to the nucleus.
21,24,25 IL-1b was also able to
rapidly induce IkB-a degradation and the consequent
NF-kB activation in the CCRF-CEM cell line (Fig. 6),
indicating that these cells respond to inflammatory
stimuli, such as IL-1b, by activating NF-kB. Therefore,
we evaluated the ability of Dex to counteract that
inflammatory stimulus and found that pretreatment of
the cells with Dex for 1 h before stimulation with IL-
1b prevented the loss of IkB-a (Fig. 6A), as well as the
formation of NF-kB /DNA complexes (Fig. 6B).
Hence, these results show that Dex efficiently pre-
vents NF-kB activation in response to inflammatory
stimuli, in CCRF-CEM cells, as previously reported for
other cell systems.
14,18,23
Since the IkB-a protein is intrinsically unstable and
rapidly degraded unless it associates with NF-kB
dimers,
1,22 it seems probable that the increased IkB-
a levels, in response to Dex, retain the NF-kB
proteins in the cytoplasm, even in the presence of a
strong inducer like IL-1b. This is in agreement with
studies in HeLa cells,
17 T lymphocytes
18 and rat
brain
22 showing that the mechanism by which GCs
prevent NF-kB activation, in response to various
stimuli, is through the induction of the expression
of IkB-a.
In summary, this study indicates that, in CCRF-CEM
cells, Dex prevents NF-kB activation induced by a
proinflammatory stimulus like IL-1b, by a negative
feedback mechanism that involves the upregulation
of IkB-a synthesis. This effect seems to depend on
the early and transient activation of NF-kB, and is not
mediated by the intracellular GC receptors.
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